Antiretroviral Activity of the Anti‐CD4 Monoclonal Antibody TNX‐355 in Patients Infected with HIV Type 1 | Zendy

Daniel R. Kuritzkes | Zendy; Jeffrey M. Jacobson | Zendy; William G. Powderly | Zendy; Eliot Godofsky | Zendy; Edwin DeJesus | Zendy; Frances F Haas | Zendy; Keith A. Reimann | Zendy; Jeffrey L. Larson | Zendy; Patrice O. Yarbough | Zendy; Valentin Curt | Zendy; William Shanahan | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Antiretroviral Activity of the Anti‐CD4 Monoclonal Antibody TNX‐355 in Patients Infected with HIV Type 1

Author(s) -

Daniel R. Kuritzkes,

Jeffrey M. Jacobson,

William G. Powderly,

Eliot Godofsky,

Edwin DeJesus,

Frances F Haas,

Keith A. Reimann,

Jeffrey L. Larson,

Patrice O. Yarbough,

Valentin Curt,

William Shanahan

Publication year - 2004

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1086/380802

Subject(s) - antibody , monoclonal antibody , virology , medicine , viral load , dosing , human immunodeficiency virus (hiv) , lentivirus , immunology , viral disease

We wished to determine the safety and anti-human immunodeficiency virus (HIV) type 1 activity of single doses of TNX-355, a humanized IgG4 anti-CD4 monoclonal antibody with potent activity against HIV-1 in vitro, in HIV-infected subjects.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research